37.82  0.48 (1.29%)		04-26 12:31
Open: 37.09 High: 37.82 Volume: 30,808		Pre. Close: 37.34 Low: 37.09 Market Cap: 1,264(M)

Short term
Mid term
Targets	6-month :	48.75	1-year :	52.45
Resists	First :	41.73	Second :	44.9
Pivot price	38.43
Supports	First :	36.61	Second :	30.45
MAs	MA(5) :	38.39	MA(20) :	39.23
	MA(100) :	42.45	MA(250) :	23.69
MACD	MACD :	-1.5	Signal :	-1.6
%K %D	K(14,3) :	24.4	D(3) :	31.6
RSI	RSI(14): 40.5
52-week	High :	53.81	Low :	3.38

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ SLNO ] has closed above bottom band by 33.5%. Bollinger Bands are 39.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	38.56 - 38.78	38.78 - 38.95
Low:	36.75 - 37.01	37.01 - 37.23
Close:	36.95 - 37.34	37.34 - 37.67

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Tue, 23 Apr 2024
Soleno Therapeutics (NASDAQ:SLNO) Stock Price Passes Below 50-Day Moving Average of $43.74 - MarketBeat

Mon, 22 Apr 2024
Soleno Therapeutics Board Member to Step Down Peacefully - TipRanks.com - TipRanks

Thu, 04 Apr 2024
Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO) - Yahoo Finance

Thu, 04 Apr 2024
CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO) - Yahoo Finance

Fri, 08 Mar 2024
We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn - Simply Wall St

Wed, 14 Feb 2024
Should Biotechnology Stock Soleno Therapeutics Inc (SLNO) Be in Your Portfolio Wednesday? - InvestorsObserver

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	32 (M)
Shares Float	13 (M)
Held by Insiders	2 (%)
Held by Institutions	97.6 (%)
Shares Short	2,760 (K)
Shares Short P.Month	1,680 (K)

EPS	-2.36
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.96
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-23.4 %
Return on Equity (ttm)	-46.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.14
Qtrly Earnings Growth	0 %
Operating Cash Flow	-25 (M)
Levered Free Cash Flow	-13 (M)

PE Ratio	-15.95
PEG Ratio	-1.6
Price to Book value	7.57
Price to Sales	0
Price to Cash Flow	-48.98

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.